Dudediligence.

Kyverna Therapeutics, Inc

KYTXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$632,380

5 notices · 70,669 sh

Oct 2025 to Oct 2026

Reported ·

$292,776

1 sale · 2 buys · $1,999,995 bought

Oct 2025 to Jun 2026

The two figures cover different periods.

The one reported sale carries the 10b5-1 box. It is 0.04% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-04-17: KAREN WALKER, Form 1442026-04-14: KAREN WALKER, Form 1442026-04-07: DANIEL SPIEGELMAN, Form 1442026-03-31: DANIEL SPIEGELMAN, Form 1442025-12-15: KAREN WALKER, Form 1442025-12-15: Walker Karen Marie, sold2025-12-18: Westlake BioPartners Fund I, L.P., bought2025-12-18: SEIDENBERG BETH C, bought
under a no plan named▼ sale▲ buysize is dollars

Form 144 notices, newest first

2026-04-17KAREN WALKER, Chief Technology Officer$95,300
10,000 shplan 2025-09-12Form 4s on file end Jun 23144 ↗
2026-04-14KAREN WALKER, Chief Technology Officer$23,336
2,459 shplan 2025-09-12Form 4s on file end Jun 23144 ↗
2026-04-07DANIEL SPIEGELMAN, Director$162,637
17,578 shno plan dateForm 4s on file end Jun 23144 ↗
2026-03-31DANIEL SPIEGELMAN, Director$140,404
16,634 shno plan dateForm 4s on file end Jun 23144 ↗
2025-12-15KAREN WALKER, Chief Technology Officer$210,702
23,998 shplan 2025-09-12144 ↗
Form 4, 2025-12-17: sold 23,998 at $12.20 Form 4 ↗